Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

• Autores principales: Yasuhiko Koga (Autor), Haruka Aoki-Saito (Autor), Yosuke Kamide (Autor), Makiko Sato (Autor), Hiroaki Tsurumaki (Autor), Masakiyo Yatomi (Autor), Tamotsu Ishizuka (Autor), Takeshi Hisada (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma. While high-dose mepolizumab is also indicated for EGPA, benralizumab is indicated only for severe asthma. Benralizumab is charact...